PlaqueTec’s BIOPATTERN trial passes 100 patients and expands to 8 NHS centers

PlaqueTec, a medtech company pioneering intracoronary liquid biopsy to reveal the biological drivers of atherosclerotic cardiovascular disease (ASCVD), today announced that its BIOPATTERN clinical trial has recruited its 100^th patient and expanded to eight NHS specialist cardiac centers. St Bartholomew's Hospital, London, and Leeds General Infirmary are now recruiting, with Blackpool Victoria and Queen Elizabeth Birmingham set up and ready to start. BIOPATTERN aims to uncover the patient-specific mechanisms driving coronary artery disease (CAD) and identify novel drug targets for personalized medicines. Recruitment towards the 300-patient target is expected to complete in 2027.

CAD is the most common form of ASCVD, the world's leading cause of death. Yet treatment remains largely one-size-fits-all, leaving many patients at risk of a heart attack. BIOPATTERN uses PlaqueTec's Liquid Biopsy System^™ (LBS) to sample blood directly at the site of coronary plaque. Measuring thousands of biomolecules where the disease is happening gives a more accurate, disease-specific picture than systemic samples can provide.

These data feed BioCarta, PlaqueTec's growing repository of unique intracoronary proteomic and clinical data, which will help define and diagnose patient sub-groups and new therapeutic targets to guide patient stratification and drug development.

The additional centers join Royal Papworth Hospital, Cambridge; Norfolk and Norwich University Hospital; Royal Bournemouth Hospital; and the Bristol Heart Institute, extending BIOPATTERN's network across England. The trial is run by Papworth Trials Unit Collaboration with PlaqueTec and overseen by a Trial Steering Committee chaired by Professor Peter Libby (Mallinckrodt Professor of Medicine, Harvard Medical School, and President of the International Atherosclerosis Society).

Dr. Stephen Hoole, Consultant Cardiologist, Royal Papworth Hospital, and BIOPATTERN trial Chief Investigator, commented: "One-size-fits-all treatment for coronary disease leaves many patients carrying significant residual risk. PlaqueTec's site-of-disease approach aims to reveal the mechanisms underlying disease in individual patients, and holds real potential to drive a new generation of precision medicines for atherosclerotic disease."

BIOPATTERN aims to close the knowledge gap in CAD and pave the way for precision therapies where unmet need remains high. Passing 100 participants and growing to eight NHS centers is important progress. We're grateful to our NHS clinical partners and to every patient taking part."

Dr. Simon Williams, General Manager, PlaqueTec